Antagonist mineralokortikoidnih receptora eplerenon u suvremenom liječenju kardiovaskularnih bolesnika.

Mineralocorticoid Receptor Antagonist Eplerenone in Cardiovascular Disease.

Aldosterone and eplerenone are mineralocorticoid receptor antagonists with one of the main roles in the treatment of heart failure, as demonstrated by large randomized controlled trials. Effects on patient outcomes are the result of blocking the renin-angiotensin-aldosterone system, which improves cardiac remodeling. Besides heart failure, mineralocorticoid receptor antagonists are used in treatment of patients with resistant arterial hypertension. This review focuses on the pharmacokinetics, pharmacodynamics, clinical effects, and safety profile of eplerenone. [ABSTRACT FROM AUTHOR]

Velika randomizirana kontrolirana istraživanja dokazala su središnju ulogu antagonista mineralokortikoidnih receptora spironolaktona i eplerenona u liječenju bolesnika sa zatajivanjem srca. Svoje brojne pozitivne učinke ostvaruju blokiranjem reninsko-angiotenzinsko-aldosteronskog sustava, što uzrokuje smanjenje negativne remodelacije miokarda te u konačnici bolje ishode za bolesnika. Osim u zatajivanju srca, antagonisti mineralokortikoidnih receptora imaju ulogu u liječenju bolesnika s rezistentnom hipertenzijom. Ovaj pregledni članak usredotočen je na farmakokinetiku, farmakodinamiku, kliničku primjenu i sigurnosni profil eplerenona. [ABSTRACT FROM AUTHOR]

Copyright of Cardiologia Croatica is the property of Croatian Cardiac Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)